A method of treating cardiac arrhythmias

 

(57) Abstract:

The invention relates to medicine, particularly cardiology. The purpose of increasing the effectiveness of therapy in children with cardiac arrhythmias. To do this, identify indicators, glutathione peroxidase, superoxide dismutase and malonic aldehyde and at higher glutathione peroxidase and malonic aldehyde, the reduction of superoxide dismutase administered capsules resurrection on a 2 to 3 times a day and Riboflavin 5 mg two or three times a day, treatment 14 to 21 days. table 1.

The invention relates to medicine, namely to the treatment of cardiac arrhythmias.

There are various methods to treat cardiac arrhythmias. Used anti-arrhythmic drugs, which are divided into 4 groups: 1) membranostabiliziruyuschee that suppress the activity of ectopic foci, most of the drugs (quinidine, procainamide, etmozin, aymalin, lidocaine, phenytoin); 2) In-adrenoblokatory (obzidan, inderal, inderal, and others); 3) cordarone (amiodarone) antiadrenergicheskoe agent, providing non-competitive - and-blocking action; 4) calcium antagonists (isoptin), which reduces the velocity of propagation of excitation in the AV connection, allidiostominae drugs (beatamines) drugs potassium (Panangin, asparkam), cardiac glycosides, anabolic hormones, etc. But all of these drugs have no effect on the stabilization of membranes, prevent the formation of ionophores in the cell.

As a prototype adopted a method of treating cardiac arrhythmia, comprising introducing into a patient drug cordarone in the amount of 5-8 mg/kg, providing a - and b-blocking action. This method is most effective existing, as it allows to normalize heart rhythm in a fairly short period of time.

However, the known method has a number of disadvantages:

the cordarone has a high cumulative effect, after receiving continue in effect for about two weeks.

develops severe cordaronebuy pneumopathy with respiratory failure;

is decrease heart rate, lengthening of interval Q, sometimes when the accumulation in the body of a large number of cordarone may occur ventricular arrhythmia;

increased photosensitivity;

disturbed function of the thyroid: Hyper-, hypothyroidism.

there keratopathy;

discoloration of the skin, stanowice remission due to the stabilization of cytomembrane.

This objective is achieved in that in the method of treating cardiac arrhythmias by introduction into a patient of drugs, the patient examine the blood, where determine the activity of the antioxidant enzymes superoxide dismutase (SOD) and glutathione peroxidase (GPX) and quantity of the finished product lipoperoxidative malondialdehyde (MDA) and increase of SOD activity decrease of SOD activity and increase the number of MDA, it is also prescribed capsules resurrection 1 capsule 2 to 3 times a day and Riboflavin 5 mg 2-3 times a day, treatment 14-21 day.

Was investigated range of blood on the specified parameters. Through numerous studies, it was found that when the heart rhythm change properties of antioxidant protection of cardiomyocytes, namely, decreased activity of SOD and the amount of MDA, increased activity of the DPP.

Based on the identified patterns, it was decided to use antioxidant tools for the treatment of cardiac arrhythmias. This is because the circulatory organs are physiologically due to contact with oxygen, thereby incurring his permanent toxic effect.

In cachetemplate).

It is known that Riboflavin increases the efficiency of the antioxidant protection of the myocardium itself as a powerful antioxidant coenzyme natural cytosolic antioxidant enzyme glutathione peroxidase, which, if ingested, increases its activity, has a positive effect on the permeability of membranes, reduces the activity of the processes of lipoperoxidation in the body, reduces toxic membraneelectrode the action of reactive oxygen species such as superoxide anion radical.

First, it was found that Riboflavin contributes to the stabilization of cytomembrane, thus increasing the antiarrhythmic effects of capsules of the resurrection. Thus, the first proposed method for the treatment of heart rhythm disorders at the cellular level, resulting in stabilization of heart rhythm and prolonged remission. It is established that the capsules of the resurrection have antioxidant effects, as well as anti-arrhythmic, and Riboflavin enhances this effect, closing pathologically formed additionally functioning ion channels.

It is known the use of capsules of the resurrection in ischemic heart disease. Riboflavin uses"ptx2">

In the known patent and scientific and medical literature is not found technical solutions that would apply vitamin b2as an antiarrhythmic drug. Therefore the proposed solution meets the criterion of "substantial differences".

Capsules resurrection consist of 50 mg of ascorbic acid, 250 mg glutamic acid; 30 mg of rutin, tocopherol-acetate 1 mg/kg Doses of drugs correspond to the doses given in the reference M. D. Mashkovsky. "Medicinal product".

Capsules and Riboflavin are assigned 2-3 times a day depending on age within 14-21 days.

The method is as follows. In a patient with a preliminary diagnosis of "cardiac rhythm" after clinical and functional examination is taken blood from a vein on the antioxidant EDTA 2 ml separated serum, which is determined by the amount of MDA is the end product of lipid peroxidation. The blood from the capillary veins in the amount of 0.1 ml is taken in buffered water and measured the activity of antioxidant enzymes superoxide dismutase and glutathione peroxidase. When the decrease of SOD activity and increased activity of SE and in the day and Riboflavin 5 mg 2-3 times daily for 14-21 days. Then again measured parameters lipoperoxidative, if they have not come to normal, and along with this there are clinical changes, continues antioxidant therapy for another 2 weeks.

Examined 51 patients with cardiac rhythm disorders ages 3 to 15 years. The control group consisted of 25 healthy children of the same age.

20 children were prescribed course of treatment approach, i.e., capsules resurrection and Riboflavin. 16 children were in the complex therapy: anti-oxidant together with traditional and 15 children in traditional therapy. Treatment was administered an average period of 16 days patients were on antioxidant therapy, and 24 days for patients who were on a holistic and traditional therapies. All observed patients were discharged in good condition.

Follow-up examination was performed after 1, 3, 6 months.

The absence of cardiac arrhythmias in patients who were on anti-oxidant therapy (20), was diagnosed in 16 children 5 significant decrease PVCs to 2-3 per minute and only 1 patient had a relapse of the disease.

In the group of patients who were on combination therapy (16), LASS="ptx2">

To confirm the advantages of the proposed method for the comparative analysis, the data which are summarized in the table.

The table shows that the proposed method is more effective, allows to achieve a rapid improvement of patients ' health, prevent the development of recurrent disease.

In addition to clinical improvement was observed normalization of biochemical parameters of processes lipoperoxidative.

P R I m m e R. So Sick for 13 years, and/b N 769 was admitted in the hospital N 7, office No. 6 with a diagnosis of heart rhythm arrythmia (algoritmi), dystonia puberty. History of the girl frequent stabbing pain in the heart for 3 years, shortness of breath during physical activity, a feeling of shortness of breath, fatigue. Treatment is not received. During the next bout of pain in my heart was made ECG revealed a heart rhythm disorder and hospitalized.

Genealogical history burdened by cardiovascular disease on both sides.

When viewed in a languid, pale, paraorbital cyanosis, marbling of the skin on the anterior chest wall, pink speaker dermographism, Diana with the front arms. The back wall of the pharynx natural colouring (ENT medical consultation: Chr. tonsillitis, compensated form). Vesicular breathing in lungs, percutere pulmonary sound. Heart area is not visibly changed, the border of cardiac dullness in the age norm. The sonorous tones, accent 22 tone on the pulmonary artery, functional systolic murmur with a maximum to the left of the sternum in the 3rd intercostal space. Listen extrasystoles every 2-3 shots. The abdomen is soft. Physiological necessity normal. HELL 100/60. Neurological status without features.

When functional, the survey found: ECG analysis allowed us to detect supraventricular extrasystoles type of bigemeny. Echocardiography abnormalities not revealed, Ahoah additional echo signals up to 60% EEG prone to paroxysmal activity diencephalic region. When examining the fundus is detected tortuous arteries and varicose veins. X-rays are allowed to set the amplification pattern of finger impressions in the parietal and occipital regions. Clinical blood and urine abnormalities no. In addition, the analysis of indicators of lipoperoxidative body, which showed increased activity of the antioxidant enzyme is dialdehyde. Thus, the final diagnosis: cardiac rhythm arrythmia (algoritmi) neuro Genesis. XP. tonsillitis compensated form.

The child was initially carried out following treatment: bellataminal, Panangin, Riboxin in the age dosages, physical electrophoresis with sodium bromide on the collar zone N 10. This treatment she received in two weeks.

She feels has improved, but significant functional data have not changed. The number of extrasystoles remained the same, i.e., arrythmia were in the nature of trigemini and Ahoah continued to register additional Echo signals. There has been little movement on antioxidant enzymes activity and the amount of malondialdehyde.

Next to the specified treatment was added antioxidant therapy that the child received 3 times a day for 2 weeks.

After 2 weeks she was discharged in good condition, on a long ribbon (100 complexes) were registered only 2 extrasystoles.

During the follow-up examination after one and three months frequency of extrasystoles not increased, attacks serdsebieniya in the pediatric clinic of the Department of Pediatrics, Calium on the basis of the CST N 7, on the basis of the children's polyclinic N 58 Voroshilovskiy district, Moscow, Republican children's rheumatology sanatorium "Malakhovka". The method is used in cardiac arrhythmias. Benchmarking the effectiveness of treatment of cardiac arrhythmias showed significant advantages of the proposed method (table).

Clinical trials have shown that the proposed method of treatment prolongs remission, reduces the number of extrasystoles, normalizes antioxidant protection of the myocardium, reduces the time of stay of the patient in the hospital from 4 to 2 weeks.

The proposed method of treatment can be widely used in cardiology departments of hospitals, sanatoriums, clinics due to ease of implementation, availability and high efficiency. The proposed method of treatment can be used in treatment with other drugs used in heart rhythm irregularities, and individual therapy.

The proposed method has the following advantages compared with the known:

significantly urejaet frequency of extrasystoles, up to their complete disappearance, while the prototype of such properties is not about the ode and more what can be said about the prototype;

enhances antioxidant protection of the myocardium that can be seen from the table (when using prototype this effect was not detected);

shortens the hospital stay.

A METHOD of TREATMENT of CARDIAC arrhythmias, including antioxidant therapy, characterized in that, to increase the effectiveness of therapy in children, identify indicators, glutathione peroxidase, superoxide dismutase and malonic aldehyde and at higher glutathione peroxidase, malonic aldehyde and reduction of superoxide dismutase administered capsules resurrection one two three times a day, Riboflavin 5 mg two or three times a day, treatment 14 to 21 days.

 

Same patents:

The invention relates to medicine and relates to a tool for the treatment of stomatitis

The invention relates to wound-healing and anti-inflammatory agent and can be used for the treatment of wounds, ulcers and burns of the mucous membranes and skin

The invention relates to new heterocyclic compounds having valuable biological properties, in particular to derive dipyrido-diazepine General formula (I)

(I) where Z is oxygen, sulfur, group NCN иNOR9where R9lower alkyl;

R1hydrogen, hydroxyl, lower alkyl, lower alkenyl, lower alkenylacyl, lower alkoxyl, lower alkanoyl, lower dialkylaminoalkyl, lower alkoxyalkyl, lower alkylthiomethyl, benzyl;

R2hydrogen, lower alkyl, lower foralkyl, lower cycloalkyl, lower cycloalkenyl, lower alkenyl, lower quinil, lower alkoxyalkyl, lower alkylthiomethyl, lower alkanoyl, cyano, phenyl, benzyl, lower alkoxybenzyl, methylsulphonyl;

R3hydrogen, hydroxyl, halogen, nitro, lower alkyl, lower alkoxy, amino, lower mono - or dialkylamino, lower alkynylamino, pyrrolidin-1-yl, pyrrolin-1 - yl, tetrahydropyridine-1-yl, morpholine-1-yl, piperidine-1-yl, methoxyphenylethylamine, methoxybenzylamine;

R4hydrogen, halogen, lower alkyl, nitro, amino;

R5hydrogen, hydroxyl, halogen, lower alkyl, lower alkoxy, trihalomethyl, lower oxyalkyl, cyano;

R8hydrogen, lower alkyl; and when Z is oxygen or sulfur, R2hydrogen, lower alkyl, lower alkenyl, lower quinil, lower alkoxyalkyl, lower alkylthiomethyl, lower alkanoyl, phenyl, benzyl, lower alkoxybenzyl; R3, R4, R5, R6, R7and R8a hydrogen atom or one of the substituents R3, R4, R5, R6, R7and R8the lower alkyl and the other substituents are hydrogen, or one of the substituents R3, R4, R5and R7the halogen and the other substituents R6and R8hydrogen, or one of the substituents R3, R4and R7nitro, and the remaining substituents R5, R6and R8hydrogen, or one of zamestitelei R3, R5and R6is hydroxyl, and the other substituents R4, R7and R8hydrogen, or one of the substituents R3, R4and R7amino and the other substituents R5, R6and R8hydrogen, or one of the substituents R3and R5alkoxy, and the other substituents R4, R6, R7and R8hydrogen, or R5lowest oxyalkyl or cyano, and R3, R4, R6, R7and R8hydrogen, or R7azido, and R3, R4, R5, R6and R83, R4and R5means butyl, and the other substituents R6, R7and R8mean hydrogen, and R6, R7and R8independently of one another denote hydrogen or lower alkyl, provided that at least one of them means hydrogen, or one of the substituents R6, R7and R8means butyl, and the other substituents R3, R4and R5mean hydrogen, R1does not mean hydrogen, lower alkyl, lower alkenyl, benzyl, lower alkanoyl, lower alkoxyalkyl and lower alkylthiomethyl, and their hydrates and pharmacologically tolerable salts have valuable biological properties, particularly an inhibitory effect on reverse transcriptase of the virus HIV-1, so that they can be used for prevention or treatment of AIDS

The invention relates to new pyridine containing heterocyclic compounds, in particular new 1,3-dioxane-5-silt derived alkenovich acids containing pyridyloxy residue attached to position 4 of the 1,3-dioxane ring

The invention relates to new nitrogen-containing heterocyclic compounds, in particular to derive hinzelin or benzodiazepina.beloe acid formula

(I) where R is hydrogen, halogen, lower alkyl or lower alkoxygroup;

And group O or S;

In group-CH2-CH2or СНR1where R1means hydrogen, lower alkyl or hydroxyl;

X is oxygen or the group NH

The Y group of the formula)qwhere R2means lower alkyl, q is 2 or 3, and their salts, in particular physiologically tolerable salts, which possess pharmacological activity, in particular activity antimuskarinovoe act occurs, and therefore can be used to treat diseases of the gastrointestinal tract and respiratory tract

The invention relates to the manufacture of dietary products based on proteins of vegetable and animal origin

The invention relates to medicine, namely to andrology and can be used with medication reduced fertility caused by primary dysfunction of the testes and insufficient production of gonadotropins
The invention relates to medicine, namely to the early diagnosis of diseases, and can be used as a way preclinical diagnosis of diseases associated with deficiency of metals in the human body
The invention relates to medicine, namely to traumatology and can be used for the local treatment of acute manifestations of traumatic arthritis and to prevent the development of degenerative changes of the joints
The invention relates to medicine, namely to traumatology and can be used for the local treatment of acute manifestations of traumatic arthritis and to prevent the development of degenerative changes of the joints

The invention relates to medicine, in particular to Oncology, and for chemotherapeutic treatment of patients with tumors of different localization

The invention relates to medicine, in particular to Oncology, and for chemotherapeutic treatment of patients with tumors of different localization

FIELD: medicine.

SUBSTANCE: method involves carrying out hernia removal in intralaminar way. Posterior longitudinal ligament defect is covered with Tacho-Comb plate after having done disk cavity curettage. Subcutaneous fat fragment on feeding pedicle is brought to dorsal surface of radix and dural sac.

EFFECT: enhanced effectiveness of treatment; reduced risk of traumatic complications.

1 dwg

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: method involves intravenously administering 0.1-1% aqueous solution of khlorin, selected from group containing photolon, radachlorine or photoditazine at a dose of 0.2-0.5 mg/kg or 0.2-1% aqueous solution of porphyrin like photogem at a dose of 0.2-1 mg/kg. Laser irradiation of blood is carried out 5-15 min later after beginning photosensitizer injection into cubital vein of one arm via laser light guide set in advance in the cubital vein of the other arm during 10-40 min at wavelength of 661-666 nm and power of 20-50 mW one session per day during 3-10 days with the aqueous solution of khlorin used as the photosensitizer, or laser irradiation of blood with wavelength equal to 630-633 nm during 10-45 min with power of 20-50 mW one session per day with the aqueous solution of porphyrin used as the photosensitizer. Repeated intravenous administration of photosensitizer is carried out 1-3 months later combined with repeated laser irradiation of blood.

EFFECT: reduced risk of tumor cells dissemination and metastasis development.

2 cl

FIELD: medicine, narcology.

SUBSTANCE: one should detect satisfaction insufficiency syndrome due to performing genetic analysis by the presence of, at least, one of the genes coding the exchange of neuromediators being the constituents of human satisfaction system. One should compensate satisfaction insufficiency due to performing, at least, one complex of physical exercises. Moreover, in case of availability of pathological gene allele of dopamine D2 receptor and/or protein gene of reverse dopamine capture in patient one should apply the complex of physical exercises including those to provide sedative effect, and in case of availability of pathological gene allele of dopamine-beta-hydroxylase protein one should apply the complex of physical exercises including those that induce an activating effect. In case of availability of pathological gene allele of dopamine D2 receptor and/or protein gene of reverse dopamine capture one should apply additional food biologically active additives based upon amino acids being the precursors of neuromediators, such as taurine, D-, L-phenylalanine in combination with 5-hydroxytryptophan, hypericin and vitamin B6, and in case of pathological gene allele of dopamine-beta-hydroxylase protein one should additionally apply food biologically active additives based upon amino acids being the precursors of neuromediators, such as: taurine, tyrosine and/or dimethylaminoethanol, lecithin and group B-vitamins. The present innovation enables to take into account pathological disease mechanism.

EFFECT: higher efficiency of prophylaxis.

14 cl, 5 ex

FIELD: medicine, anesthesiology, resuscitation.

SUBSTANCE: one should perform puncturing of epidural space at Th12-L1 level. Through the lumen of puncture needle one should introduce catheter to move it cranially at the depth of 3 cm. After that one should inject 10 ml 05%-marcaine solution to perform repeated injections per 5.0 ml every 4 h during 1-8 d. The effect is achieved due to unloading minor cycle of circulation.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine, anesthesiology, resuscitation.

SUBSTANCE: one should perform puncturing of epidural space at Th12-L1 level. Through the lumen of puncture needle one should introduce catheter to move it cranially at the depth of 3 cm. After that one should inject 10 ml 05%-marcaine solution to perform repeated injections per 5.0 ml every 4 h during 1-8 d. The effect is achieved due to unloading minor cycle of circulation.

EFFECT: higher efficiency of therapy.

2 ex

Up!